Trials / Unknown
UnknownNCT00267657
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Assessment of Interactions Between IV Methamphetamine and Reserpine
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 21 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Detailed description
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Reserpine |
Timeline
- Start date
- 2004-01-01
- Completion
- 2004-11-01
- First posted
- 2005-12-21
- Last updated
- 2017-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00267657. Inclusion in this directory is not an endorsement.